Filing Flows › Emergent BioSolutions (EBS) › MCM Product sales revenue
Emergent BioSolutions (EBS) MCM Product sales revenue by quarter
Emergent BioSolutions' MCM Product sales revenue was $59.4M in Q3 2026 (third quarter 2026), -65% from Q2 2026. Over the last 7 quarters it ranged from $58.4M (Q2 2025) to $168M (Q2 2026).
| Quarter | MCM Product sales revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $59.4M | -65% | -58% |
| Q2 2026 | $168M | +65% | +188% |
| Q1 2026 | $102M | +3% | -35% |
| Q4 2025 | $99.2M | -30% | — |
| Q3 2025 | $142M | +144% | — |
| Q2 2025 | $58.4M | -63% | — |
| Q1 2025 | $157M | — | — |
Q3 2026 at a glance
Emergent BioSolutions, Q3 2026: revenue $110M (-52% year over year), operating margin -33.9%, net loss $32.7M, operating cash flow $100M. The chart follows the revenue to costs, profit and cash.
Questions
What is Emergent BioSolutions' MCM Product sales revenue?
Emergent BioSolutions' MCM Product sales revenue was $59.4M in Q3 2026 (third quarter 2026), -65% from Q2 2026.
How has Emergent BioSolutions' MCM Product sales revenue changed?
Over the last 7 quarters it ranged from $58.4M (Q2 2025) to $168M (Q2 2026).